Je was op zoek naar: aspire (Estisch - Engels)

attract ja aspire.
attract and aspire.

aspire pharma limited pharmathen s.a.
pharmathen s.a.

aspire pharma ltd tel: +44 1730 231148
aspire pharma ltd

Üle 90% patsiente uuriti aspire uuringus röntgenoloogiliselt vähemalt 2 korda.
in aspire, more than 90% of patients had at least two evaluable x-rays.

Ü le 90% patsiente uuriti aspire uuringus röntgenoloogiliselt vähemalt 2 korda.
in aspire, more than 90% of patients had at least two evaluable x-rays.

andmed annuse tiitrimise kohta reumatoidartriidi korral saadi uuringutest attract, aspire ja start.
data to support dose titration in rheumatoid arthritis come from attract, aspire and the start study.

we aspire to attain the highest degree of professional excellence , in an environment of equal opportunities .
we aspire to attain the highest degree of professional excellence , in an environment of equal opportunities .

kliinilises uuringus reumatoidartriidiga patsientidel (aspire) tuli esimesed 3 infusiooni manustada 2 tunni jooksul.
in a clinical study of patients with rheumatoid arthritis (aspire), infusions were to be administered over 2 hours for the first 3 infusions.

infliksimabi efektiivsust on hinnatud kahes mitmekeskuselises, randomiseeritud, topeltpimedas keskses kliinilises uuringus: attract ja aspire.
the efficacy of infliximab was assessed in two multicentre, randomised, double-blind, pivotal clinical studies: attract and aspire.

kliinilises uuringus reumatoidartriidiga patsientidel (aspire) tuli esimesed 3 infusiooni manustada 2- tunniste perioodide kaupa.
in a clinical study of patients with rheumatoid arthritis (aspire), infusions were to be administered over 2 hours for the first 3 infusions.

tabel 4 mõju näitajatele acr- n; struktuurne liigeskahjustus ja füüsiline funktsioon 54- ndal nädalal, aspire infliksimab + mtx platseebo
19 table 4 effects on acrn, structural joint damage and physical function at week 54, aspire infliximab + mtx subjects randomised percentage acr improvement

aspire uuringus hinnati 54-ndal nädalal ravivastust 1004-l varasemalt metotreksaadiga ravimata, varase (haigus kestnud ≤ 3 aasta, keskmiselt 0,6 aastat) aktiivse reumatoidartriidiga patsiendil (keskmine turses ja valulike liigeste hulk vastavalt 19 ja 31).
the aspire study evaluated responses at 54 weeks in 1,004 methotrexate naive patients with early (≤ 3 years disease duration, median 0.6 years) active rheumatoid arthritis (median swollen and tender joint count of 19 and 31, respectively).